<img src="https://ml.globenewswire.com/Resource/Download/20ee0f50-7288-4f81-8546-f2ad2050ddbf?size=2" nborder="0" align="left" hspace="5" vspace="5" title="OCUL Logo.jpg" alt="Ocular Therapeutix, Inc."/>BEDFORD, Mass., Sept. 01, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026. Upcoming Investor Conferences: Wells Fargo 21st Annual Healthcare Conference: Date: Thursday, September 10, 2026 Ocular Therapeutix to host investor one-on-one meetings Location: Boston, MA Baird 2026 Global Healthcare Conference: Date: Tuesday, September 15, 2026 Fireside Chat: 10:50 – 11:20 AM EDT Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO Location: New York, NY A live webcast of the Baird fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation. Upcoming Scientific Conferences: The Retina Society 59th Annual Scientific Meeting: September 23 – 26, 2026 Los Angeles, CA <ul type="disc"><li>Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial Session: AMD I Presentation Date/Time: Thursday, September 24, 2026, 11:30 – 11:34 AM PDT Presenter: Dilsher S. Dhoot, MD</li></ul> Ophthalmology Futures Forums (OFF) Retina Forum 2026: September 30, 2026 Vienna, Austria <ul type="disc"><li style="margin-top:12pt;">Presentation: Ocular Therapeutix: Redefining the Retina Experience Presenter: Nadia K. Waheed, MD, MPH, Chief Medical Officer, Ocular Therapeutix</li></ul> Euretina Innovation Spotlight (EIS): September 30, 2026 Vienna, Austria <ul type="disc"><li style="margin-top:12pt;">Presentation Title: Ocular Therapeutix: Redefining the Retina Experience Presenter: Peter K. Kaiser, MD, Chief Development Officer, Ocular Therapeutix</li></ul> 26th Euretina Congress: October 1 - 4, 2026 Vienna, Austria <ul type="disc"><li style="margin-top:12pt;">Presentation Title: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial  Session: AMD/CSC Session Date/Time: Friday, October 2, 2026, 13:24 – 13:30 PM CEST Presenter: Adnan Tufail, MBBS, MD, FRCOphth</li></ul> <ul type="disc"><li style="margin-top:12pt;">Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control Symposium Date/Time: Friday, October 2, 2026, 9:45 – 10:45 AM CEST Faculty: Arshad M. Khanani, MD, MA, FASRS; Patricio G. Schlottmann, MD; Adnan Tufail, MBBS, MD, FRCOphth; Dilsher S. Dhoot, MD</li></ul> Exact medical conference presentation times may be subject to change. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors &amp; Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations <a href="https://www.globenewswire.com/Tracker?data=7iAvXf9VLkLcUTHPFNotKBJ94qihMHo4_TjQNLmiZyMROkPYIrOIdgWV1eg6KlxKcU7lqmaeDIlD1vdVFhEsOF2-5b_DI9EBzLw2TqbjpPY=" rel="nofollow" target="_blank" title="bslattery@ocutx.com">bslattery@ocutx.com</a> <img alt="" src='https://ml.globenewswire.com/media/NzMwMGE2YmYtNTdkMy00NmEwLTk0YmYtODE1ZWI3YzY4MGQ5LTEwMjI2MjktMjAyNi0wOS0wMS1lbg==/tiny/Ocular-Therapeutix-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn